Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of DBV.PA is 1.6 and suggests 31% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Buy
Sell